INVESTOR RELATIONS

Investor relations

NEWS

Lipum (publ) announce today that the project “Identifying proteomic biomarkers to predict the course of early RA” has been granted 2,8 MSEK...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
An Extraordinay General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (“Lipum” or the “Company”)...
Lipum has developed the drug candidate SOL-116 with the aim of treating inflammatory diseases in a new way. This is based on the discovery of a unique...
The Board of Directors of Lipum AB (publ) (“Lipum” or the “Company”) unanimously recommends the shareholders of Lipum not to accept...
Lipum announces that the first patient with rheumatoid arthritis (RA) has been enrolled and dosed with SOL-116 or placebo in the ongoing phase I clinical...
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...
Lipum AB (publ) has published the interim and the year-end report for 2023. Below is a summary, a complete report (only in Swedish) is available on the...

INVESTOR RELATIONS

Investor relations